PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=2&type=section&id=ITEM%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited consolidated financial statements for the quarter ended March 31, 2024, detailing a net loss of **$1.9 million**, an improvement from **$2.4 million** in the prior-year period, driven by higher revenues and improved gross margins [Balance Sheets](index=2&type=section&id=Balance%20Sheets) As of March 31, 2024, total assets were **$27.5 million**, slightly down from **$28.5 million** at year-end 2023, primarily due to reduced cash, while liabilities increased and equity decreased reflecting the net loss Balance Sheet Data | Balance Sheet Data | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $10,820,317 | $11,482,240 | | Total Current Assets | $19,479,262 | $20,255,929 | | Total Assets | $27,500,548 | $28,460,972 | | **Liabilities & Equity** | | | | Total Current Liabilities | $4,852,927 | $4,454,278 | | Total Liabilities | $8,383,017 | $8,107,201 | | Total Stockholders' Equity | $19,117,531 | $20,353,771 | [Statements of Operations](index=3&type=section&id=Statements%20of%20Operations) For the three months ended March 31, 2024, net revenues increased **10.9%** to **$8.2 million**, gross profit grew **23.1%** to **$5.1 million**, and the net loss narrowed to **$1.9 million**, or **($0.04)** per share, from **$2.4 million** in Q1 2023 Statement of Operations | Statement of Operations | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Net Revenues | $8,197,798 | $7,392,605 | | Gross Profit | $5,103,298 | $4,147,035 | | Net Operating Loss | ($1,961,366) | ($3,056,828) | | Net Loss | ($1,935,958) | ($2,410,885) | | Net Loss Per Share (Basic & Diluted) | ($0.04) | ($0.05) | [Statements of Cash Flows](index=4&type=section&id=Statements%20of%20Cash%20Flows) Net cash used in operating activities significantly decreased to **$0.35 million** in Q1 2024 from **$4.66 million** in Q1 2023, reflecting improved operating results and working capital management, with the quarter ending with **$10.8 million** in cash Cash Flow Activity | Cash Flow Activity | For the Three Months Ended March 31, 2024 | For the Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Net Cash Used in Operating Activities | ($346,720) | ($4,660,583) | | Net Cash Used in Investing Activities | ($133,083) | ($283,837) | | Net Cash Used in Financing Activities | ($182,120) | ($238,972) | | Net Decrease in Cash | ($661,923) | ($5,183,392) | | Cash and Cash Equivalents, End of Period | $10,820,317 | $12,224,865 | [Statements of Stockholders' Equity](index=5&type=section&id=Statements%20of%20Stockholders'%20Equity) Stockholders' equity decreased from **$20.4 million** at year-end 2023 to **$19.1 million** as of March 31, 2024, primarily due to the **$1.9 million** net loss - Total stockholders' equity decreased from **$20,353,771** on December 31, 2023, to **$19,117,531** on March 31, 2024[19](index=19&type=chunk) - The decrease was primarily caused by a net loss of **$1,935,958** for the quarter[19](index=19&type=chunk) [Notes to Financial Statements](index=5&type=section&id=Notes%20to%20Financial%20Statements) The notes detail accounting policies, a new **$10 million** HSBC loan facility, a **$6.4 million** deferred tax asset valuation allowance, and a successful regulatory appeal upholding EU sales - Revenues are derived from three sources: domestic core (US and Canada), international core, and novel therapies[38](index=38&type=chunk) - On March 8, 2024, the Company entered into a loan agreement with HSBC for a **$5 million** revolving credit facility and a **$5 million** term loan facility, with no outstanding borrowings as of March 31, 2024[74](index=74&type=chunk) - On April 8, 2024, the Company's appeal to BSI regarding a prior audit was upheld, preventing disruption of sales to the EU market[84](index=84&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=14&type=section&id=ITEM%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2024 financial results, highlighting **10.9%** revenue growth to **$8.2 million**, improved gross margin to **62.3%**, a narrowed net loss, and sufficient liquidity [Results of Operations](index=15&type=section&id=Results%20of%20Operations) Total net revenues grew **10.9%** to **$8.2 million**, driven by strong International Core performance, with gross profit rising **23.1%** to **$5.1 million** and margin expanding to **62.3%** Net Revenues by Segment | Net Revenues by Segment | Q1 2024 | Q1 2023 | Change (%) | | :--- | :--- | :--- | :--- | | Domestic Core | $5,953,865 | $5,719,135 | 4.1% | | International Core | $1,790,483 | $1,097,490 | 63.1% | | Novel Therapies | $453,450 | $575,980 | (21.3%) | | **Total** | **$8,197,798** | **$7,392,605** | **10.9%** | - Gross margin increased to **62.3%** in Q1 2024 from **56.1%** in Q1 2023, primarily driven by production efficiencies from outsourced manufacturing and consolidation of US manufacturing sites[94](index=94&type=chunk) - Operating expenses decreased by **1.9%** year-over-year, mainly due to a **5.7%** decrease in research and development expenses related to the timing of project spending[95](index=95&type=chunk)[96](index=96&type=chunk) [Liquidity and Capital Resources](index=16&type=section&id=Liquidity%20and%20Capital%20Resources) The company ended Q1 2024 with **$10.8 million** in cash, with net cash used in operating activities significantly improving to **$0.3 million** from **$4.7 million** in the prior-year quarter, ensuring sufficient liquidity for at least the next twelve months - The company's principal source of liquidity is cash on hand, which was **$10.8 million** as of March 31, 2024[99](index=99&type=chunk) - Net cash used in operating activities improved to **$0.3 million** in Q1 2024 from **$4.7 million** in Q1 2023[102](index=102&type=chunk)[103](index=103&type=chunk) - Management expects that cash on hand and cash flows from operations will be sufficient to meet requirements for at least the next twelve months[101](index=101&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=17&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company has determined that quantitative and qualitative disclosures about market risk are not applicable for this reporting period, indicating no material exposure requiring such disclosure - The company has determined that quantitative and qualitative disclosures about market risk are not applicable[108](index=108&type=chunk) [Controls and Procedures](index=17&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2024, with no material changes to internal control over financial reporting during the quarter - Management, including the Principal Executive Officer and Principal Financial Officer, concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report[109](index=109&type=chunk) - No changes in the Company's internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[110](index=110&type=chunk) PART II. OTHER INFORMATION [Risk Factors](index=17&type=section&id=ITEM%201A.%20Risk%20Factors) The company refers to the risk factors described in its Annual Report on Form 10-K for the year ended December 31, 2023, with no new or materially changed risk factors reported in this 10-Q - The company directs readers to the risk factors disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for a description of various risks and uncertainties[111](index=111&type=chunk) [Exhibits](index=17&type=section&id=ITEM%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, primarily consisting of CEO and CFO certifications required by Sarbanes-Oxley Act Sections 302 and 906, and Inline XBRL documents - The report includes certifications from the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[111](index=111&type=chunk) - Inline XBRL instance and taxonomy documents are also filed as exhibits to the report[111](index=111&type=chunk)[116](index=116&type=chunk) [Signatures](index=18&type=section&id=Signatures) - The report was duly signed and authorized on May 1, 2024, by Linda Tharby, President and Chief Executive Officer, and Thomas Adams, Chief Financial Officer and Treasurer[115](index=115&type=chunk)

EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS DELIVERING DOUBLE-DIGIT REVENUE GROWTH MAHWAH, NJ – May 1, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient- centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights "We are ...

KORU Medical Systems, Inc. (NASDAQ:KRMD) Q4 2023 Earnings Conference Call March 13, 2024 4:30 PM ET Company Participants Louisa Smith - Gilmartin Group Linda Tharby - President and CEO Tom Adams - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Alex Nowak - Craig-Hallum Capital Caitlin Cronin - Canaccord Genuity Jason Bednar - Piper Sandler Operator Good day and welcome to the KORU Medical Systems Fourth Quarter and Full Year 2023 Earnings Call. All participants will be in listen only ...

Exhibit 10.1 LOAN AND SECURITY AGREEMENT dated as of March 8, 2024 between KORU MEDICAL SYSTEMS, INC., as Borrower and HSBC VENTURES USA INC., as Bank This LOAN AND SECURITY AGREEMENT (this "Agreement") is dated as of March 8, 2024 (the "Effective Date") by and between KORU MEDICAL SYSTEMS, INC., a Delaware corporation ("Borrower") and HSBC VENTURES USA INC. ("Bank"), and provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows: Section 1 Definition ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to __________ Commission file number 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3044880 (State or other ...

KORU Medical Systems, Inc. (NASDAQ:KRMD) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Linda Tharby - Chief Executive Officer and President, Director Tom Adams - Chief Medical Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Frank Takkinen - Lake Street Capital Operator Good day. And welcome to the KORU Medical Systems Third Quarter 2023 Earnings Call. All participants will be in listen-only mode. [Operator Instruction ...

6 • Freedom60 with PFS is preferred by 78% of patients • 70% of patients are on >50 mL 15 Total Collaborations | +1/-1 in Q3 2023 $2.5B TAM(1) | 2M(2) Global Patient Population 2025 7 8 9 Submitted for regulatory approval 10 Back Order $0.3 $7.8 $7.0 (10%) $5.9 $5.8 $1.1 $1.1 $0.2 $0.8 Q3 2022 Q3 2023 Novel Therapies International Core • Decreased 2% y/y, +6% YTD • Lower consumable volumes as compared to prior year when a $0.3M backorder was cleared. • Outpaced U.S. Rx script declines driven by increased vo ...

FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-30 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3044880 ...

KORU Medical Systems, Inc. (NASDAQ:KRMD) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Gregory Chodaczek - Gilmartin Group Linda Tharby - President, CEO & Director Thomas Adams - Interim CFO, Secretary & Treasurer Conference Call Participants Jason Bednar - Piper Sandler & Co. Alexander Nowak - Craig-Hallum Operator Greetings, and welcome to the KORU Medical Systems First Quarter 2023 Earnings Call. During the presentation, all participants will be in a listen-only mode. After ...